Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAP4K3 divergent transcript (MAP4K3-DT) is a long non-coding RNA (lncRNA) gene located close to the protein-coding MAP4K3 gene, but does not code for a protein. As a lncRNA, it may play regulatory roles in gene expression, though its specific biological function, disease involvement, or pharmacological relevance is currently unknown. It is classified as a divergent transcript, meaning it is situated within a few hundred nucleotides of a protein-coding gene, typically transcribed in the opposite direction[3][5][7]. Key distinction: MAP4K3-DT is different from MAP4K3, which is a protein-coding gene also called GLK and is involved in cellular signaling, immune regulation, and has been studied as a potential therapeutic target in autoimmune diseases and cancer[1][4][8]. MAP4K3-DT, however, is a non-coding RNA and not a protein target. No evidence supports MAP4K3-DT as a receptor, enzyme, transporter, or other classical drug target[3][5][7].
Not applicable; there are no drugs targeting this lncRNA[3][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAP4K3 divergent transcript (MAP4K3-DT).